Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319016 | 0.95 | FFAR1 (0.52) | FFAR1CYSLTR2CYSLTR1BRD4PDE10A | |
| SCHEMBL16319359 | 0.94 | FFAR1 (0.52) | FFAR1CYSLTR2CYSLTR1BRD4PDE10A | |
| SCHEMBL16319333 | 0.92 | FFAR1 (0.58) | FFAR1 | |
| SCHEMBL16318891 | 0.89 | FFAR1 (0.56) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL16318769 | 0.88 | FFAR1 (0.55) | FFAR1CYSLTR2CYSLTR1DPP4 | |
| SCHEMBL16319129 | 0.87 | FFAR1 (0.54) | FFAR1CYSLTR2CYSLTR1BRD4 | |
| SCHEMBL16319424 | 0.86 | FFAR1 (0.49) | FFAR1CYSLTR2CYSLTR1BRD4 | |
| SCHEMBL16318798 | 0.85 | FFAR1 (0.59) | FFAR1 | |
| SCHEMBL16319216 | 0.85 | FFAR1 (0.53) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL16318839 | 0.84 | FFAR1 (0.49) | FFAR1CYSLTR2CYSLTR1BRD4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2816032-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | FFAR1 31/4885CYSLTR2 455/4885CYSLTR1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.